Eisele Jeffrey 4
4 · Apellis Pharmaceuticals, Inc. · Filed Dec 27, 2024
Insider Transaction Report
Form 4
Eisele Jeffrey
Chief Development Officer
Transactions
- Sale
Common Stock
2024-12-23$33.09/sh−63$2,085→ 57,145 total
Footnotes (1)
- [F1]This represents shares sold to cover tax withholding on the Restricted Stock Units released on 12/20/2024